{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:12:29Z","timestamp":1790341949251,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20240484725"],"award-info":[{"award-number":["20240484725"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFE0113500"],"award-info":[{"award-number":["2024YFE0113500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","award":["Z221100007422027"],"award-info":[{"award-number":["Z221100007422027"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171970"],"award-info":[{"award-number":["82171970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472018"],"award-info":[{"award-number":["82472018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2024CX18"],"award-info":[{"award-number":["2024CX18"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2023IR17"],"award-info":[{"award-number":["2023IR17"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2024IR07"],"award-info":[{"award-number":["2024IR07"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces A: Physicochemical and Engineering Aspects"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.colsurfa.2025.137332","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:19:32Z","timestamp":1748546372000},"page":"137332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [89Zr]Zr-DFO-Durvalumab"],"prefix":"10.1016","volume":"723","author":[{"given":"Wenpeng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-1560","authenticated-orcid":false,"given":"Fangfang","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8521-1143","authenticated-orcid":false,"given":"Xingmin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8729-4547","authenticated-orcid":false,"given":"Lei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfa.2025.137332_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.colsurfa.2025.137332_bib2","first-page":"1","article-title":"Novel therapeutic approaches for non-small cell lung cancer: an updated view","author":"Orooji","year":"2025","journal-title":"J. Drug Target"},{"key":"10.1016\/j.colsurfa.2025.137332_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.colsurfa.2025.137332_bib4","article-title":"Immunotherapeutic prospects and progress in bladder cancer","volume":"28","author":"Liu","year":"2024","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.colsurfa.2025.137332_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100765","article-title":"The impact of preoperative immune checkpoint inhibitors on kidney and bladder cancer surgeries: a systematic review","volume":"46","author":"Petzold","year":"2022","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.colsurfa.2025.137332_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115266","article-title":"Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: a systematic review and meta-analysis","volume":"218","author":"Acker","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.colsurfa.2025.137332_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the \u201call-around warrior\u201d in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.colsurfa.2025.137332_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114519","article-title":"Exosomal PD-L1 in non-small cell lung Cancer: Implications for immune evasion and resistance to immunotherapy","volume":"155","author":"Tarin","year":"2025","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.colsurfa.2025.137332_bib9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acs.bioconjchem.0c00649","article-title":"ImmunoPET of CD146 in orthotopic and metastatic breast cancer models","volume":"32","author":"Li","year":"2021","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.colsurfa.2025.137332_bib10","article-title":"ImmunoPET imaging of Nectin4 expression in gastric and bladder cancer using [64Cu]Cu-NOTA-Padcev","author":"Huang","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.colsurfa.2025.137332_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07106-4","article-title":"Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer","author":"Huang","year":"2025","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.colsurfa.2025.137332_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12951-022-01444-3","article-title":"Nectin-4-targeted immunoSPECT\/CT imaging and photothermal therapy of triple-negative breast cancer","volume":"20","author":"Shao","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.colsurfa.2025.137332_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40265-017-0749-6","article-title":"Avelumab: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.colsurfa.2025.137332_bib14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.colsurfa.2025.137332_bib15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","article-title":"Durvalumab: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.colsurfa.2025.137332_bib16","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00259-024-07036-7","article-title":"CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies","volume":"52","author":"Huang","year":"2025","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.colsurfa.2025.137332_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07167-5","article-title":"ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab\u2019)2","author":"Huang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.colsurfa.2025.137332_bib18","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1021\/acs.molpharmaceut.5c00069","article-title":"ImmunoPET imaging of Trop2 expression in bladder cancer using [64Cu]Cu-NOTA-trodelvy","volume":"22","author":"Huang","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.colsurfa.2025.137332_bib19","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.colsurfa.2025.137332_bib20","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.colsurfa.2025.137332_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/ITT.S495751","article-title":"Recent advances in immune checkpoint inhibitors for triple-negative breast cancer","volume":"14","author":"Corti","year":"2025","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.colsurfa.2025.137332_bib22","article-title":"Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo","volume":"120\u2013121","author":"Wichmann","year":"2023","journal-title":"Nucl. Med Biol."},{"key":"10.1016\/j.colsurfa.2025.137332_bib23","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/acs.bioconjchem.6b00348","article-title":"PD-L1 detection in tumors using [(64)Cu]Atezolizumab with PET","volume":"27","author":"Lesniak","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.colsurfa.2025.137332_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/1536012117718459","article-title":"Noninvasive imaging of immune checkpoint ligand PD-L1 in tumors and metastases for guiding immunotherapy","volume":"16","author":"Chatterjee","year":"2017","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.colsurfa.2025.137332_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/1536012119829986","article-title":"Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using a zirconium-89 labeled therapeutic antibody, Avelumab","volume":"18","author":"Jagoda","year":"2019","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.colsurfa.2025.137332_bib26","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-19-3137","article-title":"Probody therapeutic design of 89Zr-CX-072 promotes Accumulation in PD-L1-expressing tumors compared to normal murine lymphoid tissue","volume":"26","author":"Giesen","year":"2020","journal-title":"Clin. Cancer Res"}],"container-title":["Colloids and Surfaces A: Physicochemical and Engineering Aspects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092777572501235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092777572501235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:09:34Z","timestamp":1762330174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092777572501235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"alternative-id":["S092777572501235X"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfa.2025.137332","relation":{},"ISSN":["0927-7757"],"issn-type":[{"value":"0927-7757","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [89Zr]Zr-DFO-Durvalumab","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces A: Physicochemical and Engineering Aspects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfa.2025.137332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"137332"}}